This site is for U.S. Healthcare Professionals only.
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Poster
T-DXd
SABCS 2024 | December 10-13, 2024
A real-world study of the effectiveness and safety of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer (mBC) among racial and ethnic minorities and older populations in the United States: Trial in progress (TiP)
Poster
T-DXd
SABCS 2024 | December 10-13, 2024
Concordance between the DESTINY-Breast04/06
VENTANA 4B5 HER2 IHC clinical trial assay
and other comparator assays for HER2-low
breast cancer: Overall results of a large-scale,
multicenter, global ring study
Poster
T-DXd
SABCS 2024 | December 10-13, 2024
Effects of trastuzumab deruxtecan on health-related quality of life and neurological function in patients with HER2+ advanced/metastatic breast cancer with or without brain metastases: DESTINY-Breast12 results
Oral
T-DXd
SABCS 2024 | December 10-13, 2024
Efficacy and safety of trastuzumab deruxtecan
(T-DXd) vs physician’s choice of chemotherapy
(TPC) by pace of disease progression on prior
endocrine-based therapy: Additional analysis
from DESTINY-Breast06
Poster
T-DXd
SABCS 2024 | December 10-13, 2024
Exploratory biomarker analysis of trastuzumab
deruxtecan (T-DXd) versus trastuzumab emtansine
(T-DM1) efficacy in human epidermal growth
factor receptor 2–positive (HER2+) metastatic
breast cancer (mBC) in DESTINY-Breast03
Poster
Other/Multi
SABCS 2024 | December 10-13, 2024
HER2+ early breast cancer treatment and
outcomes by risk of recurrence: A retrospective
US electronic health records study
Poster
HER3-DXd, T-DXd
SABCS 2024 | December 10-13, 2024
ICARUS-BREAST02: A phase Ib/II, multicenter, open-label, modular study to explore the safety, tolerability, and activity of patritumab
deruxtecan (HER3-DXd) monotherapy and combinations in patients with advanced breast cancer (ABC) after progression on T-DXd
Poster
Other/Multi
SABCS 2024 | December 10-13, 2024
Incidence and treatment patterns of
high-risk HER2+ early-stage breast
cancer (eBC) in the United States
community oncology setting
Poster
T-DXd
SABCS 2024 | December 10-13, 2024
Real-world analysis of interstitial lung disease/pneumonitis in patients with HER2-positive unresectable or recurrent breast cancer treated with trastuzumab deruxtecan: All-patient
post-marketing surveillance study in Japan
Poster
Other/Multi
SABCS 2024 | December 10-13, 2024
Real-world treatment for HER2-positive (HER2+) metastatic breast cancer patients and compliance to guideline recommendations: HER2 REAL Brazil cohort
Pages:
1 2